about
What research is needed to stop TB? Introducing the TB Research MovementChallenges in the diagnosis & treatment of miliary tuberculosisMycobacterium tuberculosis: success through dormancyThe use of supplementary immunisation activities to improve uptake of current and future vaccines in low-income and middle-income countries: a systematic review protocolNonprotein structures from mycobacteria: emerging actors for tuberculosis controlVaccines against tuberculosis: where are we and where do we need to go?Regulation of TB vaccine-induced airway luminal T cells by respiratory exposure to endotoxinDiagnosis and management of miliary tuberculosis: current state and future perspectivesLysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosisProphylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosisNovel vaccination strategies against tuberculosis.Dual effect of Thymosin α 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists.Permutations of time and place in tuberculosisR&D in Vaccines Targeting Neglected Diseases: An Exploratory Case Study Considering Funding for Preventive Tuberculosis Vaccine Development from 2007 to 2014.In Silico identification of M. TB proteins with diagnostic potential.Toward novel vaccines against tuberculosis: current hopes and obstacles.Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization.Melioidosis: Clinical impact and public health threat in the tropics.The long-term effect of current and new interventions on the new case detection of leprosy: a modeling studyThe ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in miceA novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection.Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.Comparison of the predicted population coverage of tuberculosis vaccine candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a bioinformatics approach.History of BCG Vaccine.New approaches in the diagnosis and treatment of latent tuberculosis infectionAnimal welfare in studies on murine tuberculosis: assessing progress over a 12-year period and the need for further improvement.The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signalingFactors associated with the rapid implementation process of the fixed-dose combination RHZE tuberculosis regimen in Brazil: an ecological studyEnhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection.Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis.Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens.Year of birth effects in the historical decline of tuberculosis mortality: a reconsideration.Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate.Development of vaccines against burkholderia pseudomallei.A role for systems epidemiology in tuberculosis researchStereological analysis of bacterial load and lung lesions in nonhuman primates (rhesus macaques) experimentally infected with Mycobacterium tuberculosis.Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial.An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis.
P2860
Q21563033-B7D4252F-6364-4752-97E7-BF34F4469DEBQ24630463-E67081D6-8E47-4A44-899B-D9CADD25E690Q26852023-C15D47DC-15C9-400A-8585-09CB42B0481BQ26864948-F3DC80D4-541D-49B0-BB90-15465F7FEC30Q26866196-3566A9CC-87D9-4482-A3AD-195F539AC70BQ26992233-2B9CC35D-AFB2-46E1-A46B-9DAE78131A70Q28386706-CAC1D7BA-96EA-4A0E-8D7B-FBA1AB34344CQ28393022-39CE2A4F-C287-4665-BFAD-4627215667B8Q28476716-D79F3899-6B6B-4A0A-BB00-4E50AC77212CQ28744312-811C7E6E-C7AB-4C69-A12D-476D911EAF21Q30363188-BEB5E9F0-EEBC-4A73-A39A-DE5AA1B32865Q30375943-01B378C2-8FB3-4019-BB8A-CADF75A17A65Q30378562-AD60C15B-C2BE-4D70-960F-0CAE946EA80DQ30379192-F566432B-52CF-4908-B5AC-793D093058D5Q30427790-2C04427E-957D-425C-91B6-DC4E0DF8C65FQ30484783-8A8ED07F-E9CB-4633-8C8D-B3125E242DBEQ31026796-686F034F-7B83-4B3D-A69E-D36174CE5369Q33663333-1DDB8328-97B8-4E11-A6E1-5959882D5D74Q34032050-ADB4ECCD-6866-4AC1-8944-08C7D05BCC64Q34260863-5BB93CA8-49B5-465E-A19D-C7A80655232EQ34261521-F4CC3764-EFA1-4AF5-956E-2BEF4B378E9FQ34290745-599A6011-0A28-49A4-9130-A4619EBE8137Q34290885-D632FCFA-7BFB-4731-8273-81F90FDAB491Q34345342-DB43D84D-C783-4A9A-8E17-33B0168CF439Q34370165-DA0B1840-F91E-46AB-8ED1-264DBBC60508Q34419185-8D6ADA93-2DA5-41CF-BA51-284C47DB4383Q34460532-C5E77C81-7C02-465E-B672-92B691297716Q34545176-1A179EA8-D7BE-4670-AB9F-C0C7636C66BBQ34660728-DB3C668B-D4A7-41D9-B891-9F2C2E4D152CQ34700107-4F6F491F-128A-44B0-B330-2A3B7C53C6BAQ34700682-FE7CA9AF-9317-43D4-9404-20498D09DEF7Q34806664-E95281E8-6D7B-4F73-9108-7A681C47D68FQ35066463-81A10332-0754-4700-9AB3-D5FB14F852E3Q35069788-25C83B9D-8FCA-4860-AD14-EC8311CB37BDQ35135987-58135F89-401C-4207-A017-D185AFAFBB84Q35234118-EBF3E76C-C967-469F-88BB-48B8FD5541FAQ35250742-7CF15FBE-436F-48CE-B789-94D13FA2D5B0Q35543570-49E2A3A1-266C-4FD6-9EC2-B6802F79F0D4Q35551354-75860E7C-90F6-4191-86F0-480CCA4B36A3Q35634121-FE487C1D-942D-4647-9A66-823F4475D422
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New vaccines for tuberculosis.
@en
New vaccines for tuberculosis.
@nl
type
label
New vaccines for tuberculosis.
@en
New vaccines for tuberculosis.
@nl
prefLabel
New vaccines for tuberculosis.
@en
New vaccines for tuberculosis.
@nl
P1433
P1476
New vaccines for tuberculosis.
@en
P2093
Gregory Hussey
Paul-Henri Lambert
P304
P356
10.1016/S0140-6736(10)60393-5
P407
P577
2010-05-18T00:00:00Z